WEBULL

Revenues Working Against Red White & Bloom Brands Inc.'s (CSE:RWB) Share Price Following 33% Dive

Simply Wall St · 4d ago

Red White & Bloom Brands Inc. (CSE:RWB) shareholders won't be pleased to see that the share price has had a very rough month, dropping 33% and undoing the prior period's positive performance. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 33% in that time.

Following the heavy fall in price, given about half the companies operating in Canada's Pharmaceuticals industry have price-to-sales ratios (or "P/S") above 1x, you may consider Red White & Bloom Brands as an attractive investment with its 0.2x P/S ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

See our latest analysis for Red White & Bloom Brands

ps-multiple-vs-industry
CNSX:RWB Price to Sales Ratio vs Industry December 2nd 2025

What Does Red White & Bloom Brands' Recent Performance Look Like?

Revenue has risen firmly for Red White & Bloom Brands recently, which is pleasing to see. Perhaps the market is expecting this acceptable revenue performance to take a dive, which has kept the P/S suppressed. If that doesn't eventuate, then existing shareholders have reason to be optimistic about the future direction of the share price.

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Red White & Bloom Brands' earnings, revenue and cash flow.

How Is Red White & Bloom Brands' Revenue Growth Trending?

In order to justify its P/S ratio, Red White & Bloom Brands would need to produce sluggish growth that's trailing the industry.

Taking a look back first, we see that the company grew revenue by an impressive 22% last year. As a result, it also grew revenue by 9.2% in total over the last three years. So we can start by confirming that the company has actually done a good job of growing revenue over that time.

Comparing that to the industry, which is predicted to deliver 13% growth in the next 12 months, the company's momentum is weaker, based on recent medium-term annualised revenue results.

With this information, we can see why Red White & Bloom Brands is trading at a P/S lower than the industry. Apparently many shareholders weren't comfortable holding on to something they believe will continue to trail the wider industry.

What We Can Learn From Red White & Bloom Brands' P/S?

Red White & Bloom Brands' recently weak share price has pulled its P/S back below other Pharmaceuticals companies. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

In line with expectations, Red White & Bloom Brands maintains its low P/S on the weakness of its recent three-year growth being lower than the wider industry forecast. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels.

Don't forget that there may be other risks. For instance, we've identified 5 warning signs for Red White & Bloom Brands (4 are potentially serious) you should be aware of.

If you're unsure about the strength of Red White & Bloom Brands' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.